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Inter-institutional heterogeneityBackground and purpose: Although FDG-avid tumors are recognized as a potential target for dose escala-
tion, there is no clear basis for selecting a boost dose to counter this apparent radioresistance. Using a
novel analysis method, based on the new concept of an outcome-equivalent dose, we estimate the extra
dose required to equalize local control between FDG-avid and non-avid head and neck tumors.
Materials and methods: Based on a literature review, ﬁve reports of head and neck cancer (423 patients in
total), along with an internal validation dataset from our institution (135 oropharynx patients), were
used in this analysis. To compensate for the heterogeneity among multi-institutional patient cohorts
and corresponding treatment techniques, local control data of the cohorts were ﬁt to a single
dose–response curve with a clinically representative steepness (c50 = 2), thereby deﬁning an ‘outcome-
equivalent dose’ (OED) for each institutional cohort. Separate dose–response curves were then
determined for the FDG-avid and FDG-non-avid patient cohorts, and the ratio of TD50 (tumor dose
required for 50% of control) values between the high- and low-FDG-uptake groups (TD50,high/TD50,low)
was estimated, resulting in an estimated metabolic dose-modifying factor (mDMF) due to FDG-avidity.
Results: For individual datasets, the estimated mDMFs were found to be in the range of 1.07–1.62,
decreasing if the assumed slope (c50) increased. Weighted logistic regression for the six datasets resulted
in a mDMF of 1.19 [95% CI: 1.04–1.34] for a c50 value of 2, which translates to a needed dose increase of
about 1.5 Gy per unit increase in the maximum standardized uptake value (SUVm) of FDG-PET [95% CI:
0.3–2.7]. Assumptions of lower or higher c50 values (1.5 or 2.5) resulted in slightly different mDMFs:
1.26 or 1.15, respectively. A validation analysis with seven additional datasets, based on relaxed criteria,
was consistent with the estimated mDMF.
Conclusions: We introduced a novel outcome-equivalent dose analysis method to estimate the dose–
response modifying effect of FDG uptake variation. To reach equal response rates, FDG-avid tumors are
likely to require 10% to 30% more dose than FDG-non-avid tumors. These estimates provide a rational
starting point for selecting IMRT boosts for FDG-avid tumors. However, independent tests and reﬁne-
ments of the estimated dose-modifying effect, using high-quality prospective clinical trial data, are
needed.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 111 (2014) 340–347
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sa/3.0/).Many common tumors exhibit an increased glucose uptake as a
result of upregulated glycolysis [1], which can be detected via
ﬂuorodeoxyglucose positron emission tomography (FDG-PET, or
simply FDG). FDG-PET has become an important diagnostic tool
for cancer detection, staging, and target deﬁnition [2,3], as well
as for monitoring tumor response after treatment [4,5].
Although there are some contrary results [6,7], many clinical
studies have shown that the uptake of FDG, usually measured as
the maximum standardized uptake value (SUVm), is a signiﬁcantpredictor of prognosis for many tumor sites, including head and
neck cancer [8–10]. Moreover, high FDG uptake is correlated with
increased local failure and shorter survival [11–13]. The precise
mechanism causing tumors with larger SUVs to exhibit a poorer
treatment response is unknown. Tumors with a high SUV may:
(i) consist of a higher tumor cell density or greater tumor/stroma
cell ratio [14], (ii) be more metabolically active and consequently
exhibit a higher proliferation rate, (iii) be more hypoxic [15,16],
(iv) exhibit a higher DNA repair capacity [17], or some combination
of these.
Due to careful studies registering regions of local failure with
pre-treatment scans, there is some evidence that the region of high-
est FDG uptake might also be the region of highest radioresistance
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argues for the existence of tumor sub-regions corresponding to
areas of high FDG uptake, that are radioresistant, in contrast to a
shared phenotype of a particularly radioresistant tumor.
Based on clinical outcomes, the FDG-avid region in a tumor is
recognized as a possible target for dose escalation. Several plan-
ning and optimization studies have assessed the feasibility of dose
boosting on a sub-volume of a tumor, based on a FDG-PET image,
using intensity modulated radiation therapy (IMRT) [22,23]. A
key missing factor in the research on dose boosting, however, is
a useful estimate of the quantity of extra dose required to compen-
sate for FDG-avidity, compared with the population average or
FDG-non-avid tumors. In this work, we estimated the metabolic
dose-modifying factor (mDMF) due to FDG-avidity from clinical
outcome data, based on the ratio of TD50 (tumor dose required
for 50% of control) values between FDG-avid and FDG-non-avid
tumors.
In order to estimate the extra dose required to compensate for
increased FDG-avidity, we introduce a novel analysis method, we
call the ‘outcome-equivalent dose’ (OED) method. The method
accounts for the inevitable variability among radiotherapy patient
cohorts regarding patient, disease, and treatment factors. Without
accounting for these variations in local control rates, even for nom-
inally similar treatment doses, the impact of FDG-avidity would be
assumed to be constant. This is clearly not the case comparing
cohorts with overall high local control rates, where the impact of
FDG variations is small, vs. a cohort with local control rate near
50%, where the impact of FDG variation is maximized. This analysis
method is general, and therefore can be applied to estimate the
impact of other risk factors known to affect dose response in
heterogeneous cohorts, by partially compensating for the effects
of other confounding factors.Materials and methods
Inclusion criteria
A literature review was performed for reports of outcome com-
parisons between FDG-avid and FDG-non-avid cohorts diagnosed
with head and neck squamous cell carcinoma (HNSCC) and treated
with radiation therapy (RT). Initially, nearly 40 relevant studies
were identiﬁed (see Supplementary materials). We included stud-
ies in which cohorts were determined based on the maximum
standardized uptake values (SUVm) of FDG-PET and the prescribed
dose to the primary tumor and the resulting local control rate were
reported. We further restricted our analysis to studies that used
the median SUVm value as the cut-off, instead of the statistically
‘best’ cut-off value, in order to maximize consistency and reduce
consequent overestimation of effect. To date, SUVm quantiﬁcation
is not completely consistent between institutions [24], which adds
to some variability between reports. A limitation of our study is
that the effect of chemotherapy, which most deﬁnitive RT patients
receive, was not evaluable and therefore, ignored. However, clini-
cal dataset variability including treatment techniques, fraction-
ation schemes, doses, HPV status, and chemotherapy regimens,
etc., was implicitly dealt with using the ‘outcome-equivalent dose’
method.1 The SUVm values become dimensionless under the assumption that the tissue
density is 1 g/ml.Clinical datasets included
Out of the reviewed studies, 5 studies satisﬁed the inclusion cri-
teria: (i) patient cohorts with HNSCC; (ii) deﬁnitive RT with
reported prescribed dose to primary tumor; and (iii) local control
rates for high- and low-FDG-uptake groups separated by median
SUVm [25–29]. Eligibility tests for all reviewed studies are shown
in Supplementary Table 1.MSKCC internal validation dataset
In order to test the consistency of this analysis with our institu-
tional data, we included an internal validation dataset. All MSKCC
oropharynx cancer patients who were treated with deﬁnitive IMRT
with conventional fractionation in the years 2004 to 2008 were
considered for inclusion [30]. Among a total of 176 such orophar-
ynx patients with pre-treatment FDG-PET images, 41 patients were
excluded from this analysis: 39 patients who received surgery, 1
patient who died during treatment, and 1 patient whose SUVm
value was not reported. Hence, 135 patients were included in this
analysis, as shown in Table 1.
The median SUVm value for primary tumors was 13.9
[(kBq/ml)/(kBq/g)],1 and patients were separated into two groups
based on the median SUVm. Except for T-stage (p = 0.026), all other
patient characteristics were not statistically different between
these two groups. Most patients with a T1 stage fell into the lower
SUVm group, while more patients with T2 and T4 stages were clas-
siﬁed into the high SUVm group. Correspondingly, when T-stage
was separated into two groups (T1/2 vs. T3/4), the statistical differ-
ence between high- and low-FDG groups disappeared (p = 0.441).
The median primary tumor dose was 70 Gy and the median
treatment duration was 45 days. Except for 3 patients, all patients
received concurrent chemotherapy. The high rate of local control
has been reported elsewhere but may be related to HPV status
[31].
From the 5 published datasets and our internal dataset, a total
of 558 patients were thus included in this analysis; they are
summarized in Table 2.Logistic TCP model
A logistic tumor control probability (TCP) model was used to
derive dose response curves from clinical outcome data. In the
modiﬁed-logistic TCP model, the dose–response relation can be
determined by the following equation [32]:
TCP ¼ 1
1þ TD50D
 4c50 ð1Þ
where TCP is tumor control probability as a function of dose (D),
TD50 is the tumor dose required to achieve a 50% rate of control,
and c50 is the normalized slope of the TCP curve at TD50. The logistic
TCP model was applied in the estimation of the outcome-equivalent
dose, the TD50 ratio for individual clinical data, and logistic regres-
sion for whole datasets.
The clinically relevant slope of the dose response curve (c50) for
human tumors has been explored for similar patient cohorts with
different dose levels. Based on reviews of those studies, the most
likely c50 value for head and neck tumors was assessed to be about
2, with a range of 1.5–2.5 [33–36].Outcome-equivalent dose
This analysis dealt with the clinical outcomes of heteroge-
neous patient cohorts treated at different institutions with differ-
ent techniques. Therefore, direct comparison of the outcomes
based only on the nominal radiation dose was not feasible. As
shown in Table 1, the local control rates for different trials are
signiﬁcantly different, although the prescribed doses were
similar.
Other than radiation dose, many other factors might affect
treatment outcome. These include: tumor-speciﬁc factors, such
as primary tumor site, size, and stage; patient-speciﬁc factors, such
Table 1
Characteristics of internal validation dataset of oropharynx cancer patients treated with deﬁnitive radiation therapy at MSKCC (n = 135).
Characteristics Total High FDG
(SUVm > 13.9)
Low FDG
(SUVm 6 13.9)
p-Value*
# of patients 135 67 68
Gender (M/F) 117/18 57/10 60/8 0.589
Median age [range] (years) 57 [28–84] 58 [39–84] 57 [27–84] 0.735
Sub-site of primary tumor
(in oropharynx)
0.118
Base of tongue 66 37 29
Tonsil 62 28 34
Soft palate 3 2 1
Pharyngeal wall 4 0 4
T-stage 0.026
T1 12 1 11
T2 63 34 29
T3 32 16 16
T4 28 16 12
N-stage 0.396
N0 10 3 7
N1 27 15 12
N2 94 48 46
N3 4 1 3
Overall stage 0.772
II 3 1 2
III 26 14 12
IV 106 52 54
Histologic grade 0.500
G1 1 1 0
G2 48 25 23
G3 71 32 39
Unknown 15 9 6
KPS score 0.802
70 1 1 0
80 16 8 8
90 87 42 45
100 23 11 12
Unknown 8 5 3
Median SUVm [range] 13.9 [3.4–28.2] 16.9 [14.1–28.2] 9.4 [3.4–13.9] –
Median primary RT dose [range] (Gy) 70.0[67.8–70.0] 70.0[67.8–70.0] 70.0[69.9–70.0] 0.907
Median RT duration [range] (day) 45 [37–77] 45 [37–65] 45 [39–77] 0.993
Chemotherapy 0.261
Concurrent 127 64 63
Concurrent + Neoadjuvant 4 2 2
Concurrent + Adjuvant 1 1 0
None 3 0 3
Median follow-up [range] (month) 33.1 [2.0–80.9] 33.1 [2.0–80.9] 33.5 [4.0–73.6] 0.671
* Comparison between high- and low-FDG-uptake groups: v2-test, except for age, SUVm, RT dose, RT duration, and follow-up period (t-test).
342 FDG-avidity on local controlas race, age, and gender; and institution-speciﬁc factors, such as RT
technique, fractionation scheme, and chemotherapy. However, it is
impractical to evaluate the individual effect of these factors
separately.
To incorporate the effects from these factors into the analysis,
we determined an outcome-equivalent dose, instead of using the
nominal dose (Fig. 1). The equivalent dose was derived from the
total local control rate (before separating the high- vs. low-
FDG-uptake groups) of each dataset. The equivalent dose was esti-
mated from a logistic dose response curve, which was derived from
the average TD50 value of the total datasets for a typical c50 value
known for HNSCC. The total local control rate of each dataset was
projected onto the dose response curve, and the equivalent dose
was derived for each trial.Estimation of mDMF due to FDG-avidity
The mDMF of FDG-avidity was estimated from the ratio of TD50
values between FDG-avid and FDG-non-avid tumors, split by the
median SUVm values. With a known c50 value, the TD50 value can
be calculated directly from TCP data, based on Eq. (1). For an indi-
vidual trial, the mDMF was simply estimated from the following
equation:mDMF ¼ TD50;high
TD50;low
¼
Dhigh 1TCPhigh  1
 1=4c50
Dlow 1TCPlow  1
 1=4c50
¼
1
TCPhigh
 1
1
TCPlow
 1
 !1=4c50
ð2Þ
where subscripts high and low indicate the high- and low-
FDG-uptake groups. In a trial, the dose prescription was not depen-
dent on the FDG uptake group, and the Dhigh and Dlow are the same.
Also, the same c50 value was assumed for both high- and low-
FDG-uptake groups (c50,high = c50,low = c50).
The boost dose required for the high-FDG-uptake group to
achieve the same TCP as the low-FDG-uptake group was estimated
from the ratio of TD50 values (TD50,high/TD50,low). Since the same
slopes (c50) were applied to both groups, the dose ratio between
the two groups remains unchanged and is equal to the ratio of
TD50,high/TD50,low (mDMF) for any level of TCP. Therefore, the dose
required for the high-FDG-uptake group can be estimated from the
product of the prescribed dose and mDMF.
For whole-group analysis, a logistic regression was performed,
based on the logistic TCP function. Appropriate weighting, based
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J. Jeong et al. / Radiotherapy and Oncology 111 (2014) 340–347 343on standard error of population means, was applied to each clinical
datapoint, as shown in the following equation:
wi ¼ 1r2i
¼ ni
pið1 piÞ
ð3Þ
where wi is the weight of ith datapoint, ri is the standard error, pi is
the TCP, and ni is the number of patients at the datapoint. The
weight is proportional to the number of patients and increases as
the TCP approaches either end (0 or 1).
Separate local control rates (high- vs. low-FDG-uptake groups)
for each dataset were placed on the estimated equivalent dose
(Fig. 1(d)). Then, a logistic regression was performed for each group
with the same slope (c50) used for the equivalent dose estimation,
in order to ﬁnd the ratio of TD50 values between the two groups
(TD50,high/TD50,low) and the resulting mDMF.External validation with additional datasets
To further test the estimated mDMF, an additional analysis was
performed with other datasets. We applied less restrictive inclu-
sion criteria, such as: various FDG indices, including metabolic
tumor volume (MTV) or integrated SUV value; various outcome
end-points, including disease-free survival (DFS), loco-regional
control (LRC), or primary relapse-free survival (PRFS); and cohort
groupings between high- and low-FDG-uptake groups by best
cut-off. From the reviewed literature, seven studies with 329
patients were identiﬁed for the validation analysis [37–43], as
shown in Supplementary Table 2. Through the same procedure as
the original analysis, the TD50 ratio (mDMF) was estimated
between high- and low-FDG-uptake groups. The mDMF for com-
bined datasets (original and validation) was also evaluated.Results
The outcome-equivalent dose was estimated for each dataset; it
was based on the dose response curve generated by the logistic TCP
function, resulting in an average TD50 value of 59.3 and an assumed
c50 value of 2 (as described in detail in the ‘‘Outcome-equivalent
dose’’ section). Fig. 1 illustrates the method used to ﬁnd the equiv-
alent dose for each dataset. Since the average TD50 value was used
in this method, compared to the nominal dose, half of the datasets
had an increased equivalent dose and the other half had a
decreased equivalent dose. The clinical data from our institution
showed the greatest increase, by about 16%, of equivalent dose
(81.3 Gy) from a nominal dose of (70 Gy), whereas Lin et al.’s data
[26] showed the greatest decrease, by about 13%, of equivalent
dose (61.4 Gy) from a nominal dose of (70.2 Gy).
For individual datasets, the boost dose required to compensate
for a worse outcome probability, in the high-FDG-uptake group,
was found from Eq. (2). The mDMF was estimated for three differ-
ent c50 values (c50 = 1.5, 2, and 2.5), and the results are summa-
rized in Supplementary Table 3. For individual clinical data, the
estimated mDMFs were found to be in the range of 1.07–1.62, with
a tendency to decrease as the presumed slope (c50) increased up to
2.5.
With c50 = 2, which is thought to most likely represent the clin-
ical reality, the derived mDMFs were in the range of 1.09–1.44 for
each clinical datapoint. This implies that 9–44% of extra dose is
required to compensate for the radioresistance of high-FDG-uptake
tumors. Considering the prescribed dose was about 70 Gy, the total
dose required for the high-FDG-uptake group is in the range of
76.3–100.8 Gy.
Considering all the data included in this study, the TCP curves
for high- and low-FDG-uptake groups were evaluated by weighted
logistic regression analysis for three different c50 values (c50 = 1.5,
Fig. 1. The estimation of outcome-equivalent dose: (a) the local control rates of the high-FDG group (red circles), low-FDG group (blue squares), and all patients (black
triangles) for each clinical outcome data; (b) a representative logistic dose response curve estimated from the overall local control rate for all the datasets (TD50 = 59.3 Gy for
c50 = 2); (c) the equivalent dose estimated for each clinical data by aligning the total local control rate with the representative dose response curve (with the ratio of
equivalent dose to nominal dose in each parenthesis); and (d) the local control rates for high- and low-FDG groups for each clinical data at the estimated equivalent dose,
from which the TD50 value for each group and the ratio TD50,high/TD50,low were estimated based on logistic regression.
344 FDG-avidity on local control2, and 2.5). The mDMFs are shown in the last row of Supplemen-
tary Table 3, and the regression plot is shown in Fig. 2 for c50 = 2.
The ﬁtted curve for each group was consistent with the data based
on the v2-test with p-values of 0.984 and 0.977 for high- and low-
FDG-groups, respectively. The mDMF was 1.19 ± 0.08, which
means the high-FDG-uptake group requires about 19% more dose
to equalize the TCPs between low- and high-FDG-uptake groups.
For the external validation analysis, the mDMF was estimated
to be 1.20 ± 0.04 assuming c50 = 2, as shown in Supplementary
Fig. 1. When combined with the original datasets, the overall
mDMF was estimated to be 1.19 ± 0.06, with p-values (from
v2-test) of 0.998 and 1.00 for high- and low-FDG-groups, respec-
tively (Fig. 3).Discussion
Despite the well-known relationship between FDG-avidity and
increased local failure, there has been no previous estimate of
the boost dose required to offset adverse clinical outcomes in
patients with FDG-avid tumors. In this work, the boost dose was
estimated from available clinical outcome data. Assuming the
same slope in the dose response curves for both groups
(c50 = 1.5, 2, or 2.5), the boost dose required for FDG-avid tumors
to achieve the same TCP can be calculated directly from the ratio
of TD50,high/TD50,low for any TCP.
For all the datasets, the mDMF was estimated to be 1.19 for
c50 = 2, from the weighted logistic regression, which implies an
extra 19% of dose is needed for FDG-avid tumors. For example,
assuming a non-boost dose of 70 Gy, the most likely boost dose
to equalize the tumor control rate with FDG-non-avid tumorswould be approximately 83 Gy. Considering the possible variation
of the c50 value (1.5–2.5), boost doses might range between 80 Gy
and 88 Gy.
To our knowledge, this is the ﬁrst estimation from clinical out-
comes of the boost dose required for FDG-avid tumors, even
though several dose escalation studies have arbitrarily adopted
about 10–35% of extra dose for high FDG-PET sub-volumes
[22,23,44]. The result of this study provides clinical evidence of
the range of boost dose required to compensate for the FDG-
avidity. These boost doses have been shown to be feasible in these
patients with acceptable increases in NTCP, as shown by Lee et al.
[45] in the context of tumor hypoxia dose escalation.
The weighted-mean difference of the SUVm values between
high- and low-FDG-uptake groups (DSUVm) was evaluated to be
8.7, from which the extra dose required to neutralize a one-unit
increase of SUVm can be interpreted to be about 2.2%/SUVm
(c50 = 2), which is equivalent to 1.5 Gy/SUVm for a non-boost dose
of 70 Gy (see Supplementary materials for detail).
In order to analyze heterogeneous multi-institutional datasets,
we introduced a general method. The overall outcome of each
dataset was normalized in a single dose response curve, which
was derived from the average TD50 value of all the datasets and a
clinically relevant slope (c50), and the outcome-equivalent dose
was derived for each dataset. Although the nominal prescribed
doses were not signiﬁcantly different (70 Gy), the outcomes were
considerably different among the trials, and the estimated equiva-
lent dose varied signiﬁcantly. This variation seems to reﬂect the
effects of other prognostic factors, such as T-stage, chemotherapy,
HPV status, and treatment technique, which varied signiﬁcantly
among datasets. The ratio of equivalent dose to nominal dose
was between 0.87 and 1.16. This method is applicable to studying
Fig. 3. Combined analysis of both original and validation datasets for the
estimation of mDMF with c50 = 2.
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age, stage, etc.
Several potential confounding factors must be recognized in this
dataset. First, not all patients received chemotherapy, which has
been shown in multiple studies to be an important contributor to
increased overall survival. Second, these tumors consist of a heter-
ogeneous group of head and neck cancer patients ranging from clin-
ically radioresistant oral cavity cancers to the more favorable
tumors such as cancer of the oropharynx. Third, different T-stages
have been correlated with outcome, i.e., higher stage tumors do
worse than lower stage tumors [23,25], but this was not explicitly
accounted for in our dataset. In our overall logistic analysis, the
greater the fraction of patients with lower T-stage (T1–2), the
higher the estimated equivalent dose was (Supplementary Fig. 2),
as expected. Lastly, human papilloma virus (HPV) has recently been
recognized as probably the most important biomarker that predicts
tumor response in head and neck cancer [46,47]. Due to the nature
of meta-analysis and the lack of tissue conﬁrmation, however,
detailed evaluation of each factor was not possible. We judge that
the outcome-equivalent dose could account for those confounding
factors to a certain degree. Further analyses that takes into account
these factors is required to shed more light on the impact of FDG
uptake alone apart from tumor volume, HPV status, etc.
The sensitivity of the estimated TD50 ratio was tested on a range
of parameter values in the derivation of outcome-equivalent dose.
As shown in Supplementary Table 4, the variation of the TD50 value
used in equivalent dose estimation does not affect the estimated
TD50 ratio and resulting boost dose for FDG-avid tumors, since
the ratio is preserved for any TCP. Variation of the c50 value had
a modest impact on the estimation of the TD50 ratio and variations
of ±10% yielded a change of less than 2%.
In order to further test the robustness of the estimated mDMF,
we identiﬁed seven additional studies (n = 329), based on less
restrictive criteria: FDG index (SUVm or MTV); outcome end-point
(DFS, LRC, or PRFS); and cohort grouping (median or best cut-off).
From the validation datasets, the mDMF was evaluated to be 1.20,
which is almost the same as the original analysis (1.19). Also, the
combined analysis yielded the same overall mDMF as the original
analysis (Fig. 3). Although there should be inevitable differencesFig. 2. Tumor control probability (TCP) curves for high- (circles; red line) and low-
(squares; blue line) FDG-uptake groups, evaluated by weighted logistic regression
analysis with a mDMF value for c50 = 2. Note that the size of each datapoint (square
or circle) corresponds to the size of the study and the error bar indicates one
standard error (1r) for each data point. The x-error bar was estimated from the
conversion of the standard error of the total local control rate into the uncertainty
of the equivalent dose.between the two datasets, due to the different criteria applied to
the validation dataset, this additional analysis supports the meth-
odology of the study.
In this study, the slope of the dose–response curve was assumed
to be the same for both high- and low-FDG-uptake groups. How-
ever, this might not always hold, as Schütze et al. showed in their
pre-clinical study [48]. They investigated the effect of increased
radiation dose on local control depending on FDG uptake for FaDu
tumors in nude mice and concluded that the high FDG-uptake
group has a steeper dose response. To test for the effect of variable
slopes, we repeated the logistic regression with the c50 value as a
free variable (Supplementary Fig. 3). This yielded a result with a
slightly steeper dose response for the low-FDG-uptake group. This
difference with the results of Schütze et al. might be caused by the
difference in host (animal vs. human) or by the difference in frac-
tionation (single dose vs. standard fractionation). Further investi-
gations are warranted to conﬁrm the relationship between the
slope of the dose–response curve and FDG-avidity.
Publication bias for the current study was tested with a funnel
plot. In the plot, it is assumed that the studies having lower uncer-
taintywith larger sample size tend to represent the true value,while
smaller studies with larger uncertainty tend to spread on both sides
of the true value. An asymmetry in the plot implies possible publica-
tionbias in the study. In our study, thedistributionat larger standard
error seems to be asymmetric, whichmight be indicative of publica-
tion bias (Supplementary Fig. 4). Ourwork is based on published lit-
erature and all the studies included have statistically signiﬁcant
differences in outcome between high- and low-FDG-uptake groups.
Although some authors reported non-signiﬁcance [49,50], studies
that failed to achieve statistical signiﬁcancemight not be published,
leading to an overestimation of the effect.
In spite of several limitations, this study provides a feasible
approach to derive a prescription function from clinical data,
resulting in a consistent estimate. For a better estimation of the
boost dose required to compensate for FDG avidity, a more detailed
study with a larger dataset is warranted, controlling other con-
founding factors, such as primary tumor site, tumor size, chemo-
therapy, and HPV status.
Methodologically, we have introduced an entirely new analysis
method, based on ﬁnding the ‘outcome-equivalent dose’ for each
analysis cohort. The importance of this general tool is that it can
be used to estimate dose-modifying effects due to any risk factors
across heterogeneous cohorts. One example might be the
estimation of the dose-modifying factor of hypoxia. With the
346 FDG-avidity on local controlincreasing use of hypoxia-speciﬁc PET imaging such as FISO, Cu-
ATSM, and FAZA in clinical applications [51–53], a similar analysis
might be performed for an improved RT strategy to deal with
hypoxia.
Conclusion
In this work, the relationship between FDG-avidity and tumor
radiosensitivity was explored. We introduced a novel analysis
method that accounts for inter-institutional differences in non-
FDG factors, such as treatment planning, delivery, and tumor char-
acteristics, allowing for a direct estimate of the dose response
modifying effect of variation in FDG uptake. The method assumes
that the impact of the risk-factor (in this case FDG-avidity) has a
similar dose-modifying effect across heterogeneous cohorts.
Although this is not necessarily true a priori, curve ﬁtting chi-
square tests show that it is a useful approximation in this case.
The range of extra dose required for FDG-avid tumors was esti-
mated from clinical data. To reach equal response rates, FDG-avid
tumors are likely to require at least 10–30% more dose than FDG-
non-avid tumors. These estimates provide a rational starting point
for clinical trials to test the usefulness of IMRT boost for FDG-avid
tumors. However, due to the confounding effect of tumor volume/
T-stage, and other prognostic factors, independent tests of the
estimated dose-modifying effect, using high-quality prospective
clinical trial data, are needed.
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